Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Recurrence

Endometrial Neoplasms

Disease Attributes

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Antineoplastic Agents

All Drugs and Chemicals

Lenvatinib

Pembrolizumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Lenvatinib, 20 mg administered orally (PO) once daily (QD) during each 21-day cycle, and Pembrolizumab, 200 mg administered by intravenous (IV) infusion on day 1 of each 21-day cycle.

Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.

Massey Gyn Onc Team

Massey CTO Operations Managers

Leslie Randall, MD

Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants

This study is a single-arm, open-label, multicenter phase 2 trial designed to prospectively evaluate the safety and efficacy of lenvatinib in combination with pembrolizumab for mismatch repair proficient recurrent endometrial cancer in Black patients (a population under-represented on 2 FDA registration trials).

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

A Multicenter, Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib in Combination With Pembrolizumab in Black Participants With Mismatch Repair-Proficient Recurrent Endometrial Cancer

There are no plans to share individual participant data to other researchers at this time.

Number of patients evaluable for measurement of tumor response evaluated and recorded according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

Number of patients who are alive and following last dose of study treatment

Number of patients who have not had disease progression following last dose of study treatment

Number of patients who have not relapsed following last dose of study treatment

Using criteria in the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0), all AEs captured

Number of patients who discontinue treatment due to treatment-related AEs.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer	NCT05263492	Endometrial Can... Mismatch Repair... Recurrent Endom...	Lenvatinib Pembrolizumab	18 Years -	Virginia Commonwealth University
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer	NCT05263492	Endometrial Can... Mismatch Repair... Recurrent Endom...	Lenvatinib Pembrolizumab	18 Years -	Virginia Commonwealth University

Spots Global Cancer Trial Database for black participants